918538-05-3

Basic information

• Product Name: 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine
• Synonyms: Pyrrolo[2,1-f][1,2,4]triazine, 2,4-dichloro-;2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine;2,4-Dichloropyrrolo[1,2-f][1,2,4]triazine;2,4-Dichloro-pyrrolo[2,1-...;4-Dichloropyrrolo[1
• CAS NO: 918538-05-3
• Molecular Formula: C₆H₃Cl₂N₃
• Molecular Weight: 188.017
• EINECS: 1312995-182-4
• Product Categories: API intermediates
• Mol File: 918538-05-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.69
• Refractive Index: 1.733
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -5.36±0.30(Predicted)
• CAS DataBase Reference: 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine(918538-05-3)
• EPA Substance Registry System: 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine(918538-05-3)

Safety Data

• Hazardous Substances Data: 918538-05-3(Hazardous Substances Data)

Usage

General Description

2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine is a chemical compound with the molecular formula C7H3Cl2N3. It is a heterocyclic compound containing both pyrrolo and triazine rings, and it is a derivative of the widely used herbicide 2,4-dichlorophenoxyacetic acid (2,4-D). 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine is known for its herbicidal properties and is used to control broadleaf weeds in agricultural and industrial settings. It works by disrupting the growth and development of the target weeds, ultimately leading to their death. Due to its strong herbicidal activity, 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine is classified as a potentially hazardous chemical and should be handled with care to avoid adverse effects on human health and the environment.

InChI:InChI=1/C6H3Cl2N3/c7-5-4-2-1-3-11(4)10-6(8)9-5/h1-3H

Upstream product

• 1003-29-8 2-pyrrole aldehyde 
• 4513-94-4 1H-pyrrole-2-carbonitrile 
• 159326-66-6 N-amino-1H-pyrrole-2-carbonitrile 
• 159326-69-9 1-aminopyrrole-2-carboxamide 
• 1379337-32-2 1-(ethoxyformamido)-1H-pyrrole-2-carboxamide 
• 918538-04-2 pyrrolo[2,1-f][1,2,4]triazine-2,4(1H, 3H)-dione 

Downstream Products

• 1001353-78-1 (S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-2-methylpyrrolidine-2-carboxylic acid 
• 1561811-16-2 2-chloro-4-phenylpyrrolo[2,1-f][1,2,4]triazine 
• 1591741-88-6 C₁₃H₉BrClN₃O 
• 1591741-96-6 C₄₀H₃₈ClN₃O₅ 
• 1591741-98-8 C₄₂H₄₂N₄O₆ 
• 1591742-00-5 C₃₅H₃₆N₄O₆ 
• 1591741-85-3 C₁₃H₁₀ClN₃O 

Relevant articles and documents

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several comp

Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted heteroaryl compound and a composition thereof, and applications of the compound and the composition. The compound is a compound as shown in a formula I, or stereoisomer, tautomer, oxynitride, solvate, metabolite, pharmaceutically-acceptable salt or prodrug of the compound as shown in the formula I. The invention also provides a pharmaceutical composition containing the above-mentioned compound; and the above-mentioned compound and the pharmaceutical composition are capable of adjusting the activity of JAK kinases and are applied in prevention, treatment, therapy and alleviation of JAK kinase mediated diseases or disorders.